JP2013503205A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013503205A5 JP2013503205A5 JP2012527108A JP2012527108A JP2013503205A5 JP 2013503205 A5 JP2013503205 A5 JP 2013503205A5 JP 2012527108 A JP2012527108 A JP 2012527108A JP 2012527108 A JP2012527108 A JP 2012527108A JP 2013503205 A5 JP2013503205 A5 JP 2013503205A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- composition
- polypeptide
- fused
- transplant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 14
- 102000037240 fusion proteins Human genes 0.000 claims 9
- 108020001507 fusion proteins Proteins 0.000 claims 9
- 102000004965 antibodies Human genes 0.000 claims 7
- 108090001123 antibodies Proteins 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 206010018651 Graft versus host disease Diseases 0.000 claims 6
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 6
- 230000037361 pathway Effects 0.000 claims 6
- 210000000056 organs Anatomy 0.000 claims 5
- 210000001519 tissues Anatomy 0.000 claims 5
- 230000002708 enhancing Effects 0.000 claims 4
- 102000018358 Immunoglobulins Human genes 0.000 claims 2
- 108060003951 Immunoglobulins Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000001185 Bone Marrow Anatomy 0.000 claims 1
- 229960003957 Dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N Fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 101700086956 IFNG Proteins 0.000 claims 1
- 102100016020 IFNG Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 210000000447 Th1 Cells Anatomy 0.000 claims 1
- 210000000068 Th17 Cells Anatomy 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 230000000735 allogeneic Effects 0.000 claims 1
- 229960004729 colecalciferol Drugs 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 1
- 229940021056 vitamin D3 Drugs 0.000 claims 1
- 235000005282 vitamin D3 Nutrition 0.000 claims 1
- 239000011647 vitamin D3 Substances 0.000 claims 1
Claims (13)
- 被験体における移植組織または移植器官の拒絶反応を阻害または軽減するための組成物であって、
前記組成物は、第２のポリペプチドに融合した、または第２のポリペプチドに融合したリンカーペプチドに融合した、配列番号６３または配列番号６４のＩｇＶドメインを含むＢ７−Ｈ４ポリペプチドを含む融合タンパク質を含み、
前記融合タンパク質は、前記被験体においてＴｈ１経路またはＴｈ１７経路に対するＴｒｅｇの抑制効果を増強し、前記被験体における移植された組織または器官の拒絶反応を軽減するのに有効な量で存在する、
組成物。 - 被験体における移植組織または移植器官の拒絶反応を阻害または軽減するための組成物であって、
前記組成物は、第２のポリペプチドに融合した、または第２のポリペプチドに融合したリンカーペプチドに融合した、配列番号６３または配列番号６４のＩｇＶドメインを含むＢ７−Ｈ４ポリペプチドを含む融合タンパク質を含み、
前記第２のポリペプチドは、ヒトＩｇＧ１免疫グロブリンのヒンジ領域、ＣＨ２領域およびＣＨ３領域を含み、
前記融合タンパク質は、前記被験体においてＴｈ１経路またはＴｈ１７経路に対するＴｒｅｇの抑制効果を増強し、前記被験体における移植された組織または器官の拒絶反応を軽減するのに有効な量で存在する、
組成物。 - 前記融合タンパク質が、前記被験体において前記Ｔｈ１７経路に対するＴｒｅｇの抑制効果を増強するのに有効な量で存在する、請求項１または２に記載の組成物。
- 前記被験体においてＴｈ１７細胞の数を低減させる、請求項１〜３のいずれか一項に記載の組成物。
- 前記被験体においてＴｈ１細胞の数を低減させる、請求項１〜４のいずれか一項に記載の組成物。
- 前記被験体においてＩＬ−１７のレベルを低減させる、請求項１〜５のいずれか一項に記載の組成物。
- 第２の治療剤をさらに含む、請求項１〜６のいずれか一項に記載の組成物。
- 前記第２の治療剤が、グルココルチコイド、フルチカゾン、サルメテロール（ｓａｌｍｅｔｅｒｏａｌ）；ＩＬ−１２に対する抗体、ＩＬ−６に対する抗体、ＩＦＮ−γに対する抗体、ＩＬ−２３に対する抗体、ＩＬ−２２に対する抗体、ＩＬ−２１に対する抗体、およびＩＬ−４に対する抗体；ビタミンＤ３；ＣＴＬＡ−４−Ｉｇ、ベラタセプト；デキサメタゾン、ならびにその組合せからなる群から選択される、請求項７に記載の組成物。
- 前記移植が、同種異系移植である、請求項１〜８のいずれか一項に記載の組成物。
- 前記移植が、皮膚移植、組織移植、臓器移植、または骨髄移植である、請求項１〜９のいずれか一項に記載の組成物。
- 被験体における移植片対宿主病（ＧＶＨＤ）の１または複数の症状を処置するための組成物であって、
前記組成物は、第２のポリペプチドに融合した、または第２のポリペプチドに融合したリンカーペプチドに融合した、配列番号６３または配列番号６４のＩｇＶドメインを含むＢ７−Ｈ４ポリペプチドを含む融合タンパク質を含み、
前記融合タンパク質は、前記被験体においてＧＶＨＤの１または複数の症状を緩和するのに有効な量で存在する、
組成物。 - 被験体における移植片対宿主病（ＧＶＨＤ）の１または複数の症状を処置するための組成物であって、
前記組成物は、第２のポリペプチドに融合した、または第２のポリペプチドに融合したリンカーペプチドに融合した、配列番号６３または配列番号６４のＩｇＶドメインを含むＢ７−Ｈ４ポリペプチドを含む融合タンパク質を含み、
前記第２のポリペプチドは、ヒトＩｇＧ１免疫グロブリンのヒンジ領域、ＣＨ２領域およびＣＨ３領域を含み、
前記融合タンパク質は、前記被験体においてＧＶＨＤの１または複数の症状を緩和するのに有効な量で存在する、
組成物。 - 前記Ｔｈ１７経路に対するＴｒｅｇの抑制効果を増強することによって、被験体における移植拒絶反応を阻害する方法で使用するための、請求項１〜１２のいずれか一項に記載の組成物。
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23860509P | 2009-08-31 | 2009-08-31 | |
| US61/238,605 | 2009-08-31 | ||
| US25493009P | 2009-10-26 | 2009-10-26 | |
| US61/254,930 | 2009-10-26 | ||
| US26685409P | 2009-12-04 | 2009-12-04 | |
| US61/266,854 | 2009-12-04 | ||
| US28653709P | 2009-12-15 | 2009-12-15 | |
| US61/286,537 | 2009-12-15 | ||
| US37836110P | 2010-08-30 | 2010-08-30 | |
| US61/378,361 | 2010-08-30 | ||
| PCT/US2010/047384 WO2011026132A2 (en) | 2009-08-31 | 2010-08-31 | Methods and compositions for the inhibition of transplant rejection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013503205A JP2013503205A (ja) | 2013-01-31 |
| JP2013503205A5 true JP2013503205A5 (ja) | 2013-10-17 |
Family
ID=42990231
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012527108A Pending JP2013503205A (ja) | 2009-08-31 | 2010-08-31 | 移植拒絶反応を阻害するための方法および組成物 |
| JP2012527101A Pending JP2013503204A (ja) | 2009-08-31 | 2010-08-31 | Ｂ７−ｈ４融合タンパク質およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012527101A Pending JP2013503204A (ja) | 2009-08-31 | 2010-08-31 | Ｂ７−ｈ４融合タンパク質およびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US9011853B2 (ja) |
| EP (2) | EP2473523A2 (ja) |
| JP (2) | JP2013503205A (ja) |
| CN (2) | CN102666581A (ja) |
| AU (2) | AU2010286361A1 (ja) |
| CA (2) | CA2772199A1 (ja) |
| IN (2) | IN2012DN02753A (ja) |
| WO (2) | WO2011026122A2 (ja) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6891030B2 (en) | 2000-07-27 | 2005-05-10 | Mayo Foundation For Medical Education And Research | T-cell immunoregulatory molecule |
| AU2007339762B2 (en) * | 2006-12-27 | 2011-03-31 | The Johns Hopkins University | Compositions and methods for treating inflammation and auto-immune diseases |
| US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
| IN2012DN02753A (ja) | 2009-08-31 | 2015-09-18 | Amplimmune Inc | |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9518087B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| WO2012078673A1 (en) * | 2010-12-06 | 2012-06-14 | Confluence Life Sciences, Inc. | Substituted pyridine urea compounds |
| WO2012145568A1 (en) * | 2011-04-21 | 2012-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Antibodies to human b7x for treatment of metastatic cancer |
| CA2845536A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
| EP2934575A2 (en) * | 2012-12-19 | 2015-10-28 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
| AU2014265142A1 (en) | 2013-05-17 | 2015-12-24 | Medimmune, Llc | Receptors for B7-H4 |
| WO2014194293A1 (en) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
| AU2014296887A1 (en) | 2013-08-02 | 2016-01-28 | Aduro Biotech Holdings, Europe B.V. | Combining CD27 agonists and immune checkpoint inhibition for immune stimulation |
| US10370776B2 (en) * | 2013-09-25 | 2019-08-06 | Idea Orchard, Llc | Antibody like protein |
| MX2016006955A (es) * | 2013-12-02 | 2016-09-07 | Pharmacyclics Llc | Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo. |
| WO2015094782A1 (en) * | 2013-12-18 | 2015-06-25 | Albert Einstein College Of Medicine Of Yeshiva University | B7x and its derivatives for treating and preventing cardiovascular disease |
| ES2874884T3 (es) | 2014-02-21 | 2021-11-05 | Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto | Compuestos terapéuticos dirigidos a la glucosa |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| AU2015229270B2 (en) | 2014-03-12 | 2020-12-24 | Icahn School Of Medicine At Mount Sinai | Method for identifying kidney allograft recipients at risk for chronic injury |
| US9730988B2 (en) * | 2014-04-10 | 2017-08-15 | University Of Iowa Research Foundation | Parasitic biological agents for treatment and prevention of graft versus host disease |
| EP3161158B1 (en) * | 2014-06-26 | 2021-10-06 | Icahn School of Medicine at Mount Sinai | Methods for diagnosing risk of renal allograft fibrosis and rejection |
| EP3161165B1 (en) | 2014-06-26 | 2020-11-18 | Icahn School of Medicine at Mount Sinai | Method for diagnosing subclinical and clinical acute rejection by analysis of predictive gene sets, therapeutic agent for use in the treatment and kits for determining the expression |
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| EP3461337A1 (en) | 2015-05-06 | 2019-04-03 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
| CA2997442C (en) | 2015-09-04 | 2021-01-26 | Yale University | Polymeric bile acid nanocompositions targeting the pancreas and colon |
| AU2016323769B2 (en) * | 2015-09-17 | 2022-05-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Compositions comprising pregnancy specific glycoproteins and methods of use thereof |
| CA3004530A1 (en) | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| DK3429618T3 (da) | 2016-03-16 | 2024-04-22 | Amal Therapeutics Sa | Kombination af en immuncheckpoint-modulator og et kompleks som omfatter et cellepenetrerende peptid, en last og en tlr-peptidagonist til anvendelse i medicin |
| US11390675B2 (en) | 2016-09-21 | 2022-07-19 | Nextcure, Inc. | Antibodies for Siglec-15 and methods of use thereof |
| JP7346291B2 (ja) | 2016-09-21 | 2023-09-19 | アマル セラピューティクス エスエー | 癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びｔｌｒペプチドアゴニストを含む融合体 |
| EP4360714A2 (en) | 2016-09-21 | 2024-05-01 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
| US11395838B2 (en) | 2016-09-27 | 2022-07-26 | Board Of Regents, The University Of Texas System | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome |
| BR112019007365A2 (pt) | 2016-10-12 | 2019-07-09 | Univ Texas | métodos e composições para imunoterapia com tusc2 |
| WO2018099539A1 (en) | 2016-11-29 | 2018-06-07 | Horst Lindhofer | Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof |
| EP3551226A1 (en) | 2016-12-12 | 2019-10-16 | MultiVir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| US20200181225A1 (en) * | 2017-03-29 | 2020-06-11 | Sunnybrook Research Institute | Engineered t-cell modulating molecules and methods of using same |
| EP3612201B1 (en) | 2017-04-21 | 2023-10-25 | Sillajen, Inc. | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy |
| CN111108123A (zh) | 2017-05-29 | 2020-05-05 | 加马玛布斯制药公司 | 癌症相关的免疫抑制抑制剂 |
| WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| WO2018237003A1 (en) * | 2017-06-23 | 2018-12-27 | Sanford Health | METHODS FOR PRODUCING INDUCED REGULATORY T CELLS |
| JP7437301B2 (ja) | 2017-08-25 | 2024-02-22 | ファイヴ プライム セラピューティクス インク | Ｂ７－ｈ４抗体及びその使用方法 |
| JP2020535809A (ja) * | 2017-09-29 | 2020-12-10 | ナントセル，インコーポレイテッド | 抗原タンパク質及びそのための方法 |
| DK3743447T3 (da) | 2018-01-23 | 2024-05-27 | Nextcure Inc | B7-H4-antistoffer og fremgangsmåder til anvendelse deraf |
| CN108236719A (zh) * | 2018-01-29 | 2018-07-03 | 中山大学附属第三医院（中山大学肝脏病医院） | B7-h4融合蛋白在制备治疗系统性红斑狼疮药物中的用途 |
| WO2019169229A1 (en) | 2018-03-01 | 2019-09-06 | Nextcure, Inc. | Klrg1 binding compositions and methods of use thereof |
| CN111971308A (zh) | 2018-03-02 | 2020-11-20 | 戊瑞治疗有限公司 | B7-h4抗体及其使用方法 |
| KR20200135986A (ko) | 2018-03-19 | 2020-12-04 | 멀티비르 인코포레이티드 | 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물 |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| CN112292145A (zh) | 2018-03-25 | 2021-01-29 | 斯尼普生物群系有限公司 | 治疗和预防微生物感染 |
| US11572589B2 (en) | 2018-04-16 | 2023-02-07 | Icahn School Of Medicine At Mount Sinai | Method for prediction of acute rejection and renal allograft loss using pre-transplant transcriptomic signatures in recipient blood |
| CN109439626B (zh) * | 2018-11-09 | 2022-10-14 | 复旦大学附属中山医院 | 一种有助于体外获得Th22细胞的组合物及其用途 |
| JP2022513113A (ja) | 2018-11-26 | 2022-02-07 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫寛容のための組成物および方法 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| EP4162037A1 (en) | 2020-06-03 | 2023-04-12 | MV Biotherapeutics SA | Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof |
| CN116600789A (zh) | 2020-06-19 | 2023-08-15 | 耶鲁大学 | 用于诱导耐受性的聚合胆汁酸酯纳米颗粒 |
| MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
| CN114426974B (zh) * | 2020-10-29 | 2023-11-21 | 洛阳普泰生物技术有限公司 | 特异性结合非洲猪瘟病毒CD2v蛋白的抗体或抗体片段 |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
Family Cites Families (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1339281A (en) | 1920-01-26 | 1920-05-04 | Stearns | Upholstery-fold |
| GB1268212A (en) | 1968-04-19 | 1972-03-22 | Zaidan Hojin Biseibutsu | Tripeptide derivatives |
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| US4272398A (en) | 1978-08-17 | 1981-06-09 | The United States Of America As Represented By The Secretary Of Agriculture | Microencapsulation process |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US5155020A (en) | 1989-03-08 | 1992-10-13 | Health Research Inc. | Recombinant poxvirus host range selection system |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US6808901B1 (en) | 1984-09-03 | 2004-10-26 | Celltech R&D Limited | Production of chimeric antibodies |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| US4853871A (en) | 1987-04-06 | 1989-08-01 | Genex Corporation | Computer-based method for designing stablized proteins |
| US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
| US4861627A (en) | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US5750666A (en) | 1988-05-26 | 1998-05-12 | Competitve Technologies, Inc. | Polynucleotide phosphorodithioate compounds |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
| US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| US5175099A (en) | 1989-05-17 | 1992-12-29 | Research Corporation Technologies, Inc. | Retrovirus-mediated secretion of recombinant products |
| US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5204243A (en) | 1990-02-14 | 1993-04-20 | Health Research Incorporated | Recombinant poxvirus internal cores |
| US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU662298B2 (en) | 1990-09-20 | 1995-08-31 | Gilead Sciences, Inc. | Modified internucleoside linkages |
| US5296347A (en) | 1991-02-08 | 1994-03-22 | Ciba Corning Diagnostics Corp. | Bridge immunoassay |
| CA2082951C (en) | 1991-03-15 | 1999-12-21 | Robert M. Platz | Pulmonary administration of granulocyte colony stimulating factor |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5120727A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0592668B1 (en) | 1991-07-03 | 1999-03-10 | Kanebo, Ltd. | Method and device for the manufacture of a thermoplastic polyurethane elastomer |
| US5202332A (en) | 1991-08-07 | 1993-04-13 | American Home Products Corporation | Rapamycin analog as immunosuppressant |
| US5162333A (en) | 1991-09-11 | 1992-11-10 | American Home Products Corporation | Aminodiesters of rapamycin |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| AU681579B2 (en) | 1992-03-30 | 1997-09-04 | Wyeth | Rapamycin formulation for IV injection |
| US5489680A (en) | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
| US5434260A (en) | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5387680A (en) | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
| CN1135181A (zh) | 1993-09-14 | 1996-11-06 | Cytel有限公司 | 使用泛dr结合肽改变免疫应答 |
| US5385908A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
| CN1046944C (zh) | 1993-12-17 | 1999-12-01 | 山道士有限公司 | 雷怕霉素类衍生物 |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5362735A (en) | 1994-02-23 | 1994-11-08 | Smithkline Beecham Corporation | Rapamycin derivatives |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| WO1997017613A1 (en) | 1995-11-10 | 1997-05-15 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
| US5780462A (en) | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
| AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
| US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US6982323B1 (en) | 1997-12-23 | 2006-01-03 | Alexion Pharmaceuticals, Inc. | Chimeric proteins for diagnosis and treatment of diabetes |
| CA2328895A1 (en) | 1998-06-02 | 1999-12-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP1082417A4 (en) | 1998-06-04 | 2006-08-23 | Univ Queensland | GENETIC SEQUENCES MODIFYING THE PHENOTYPE |
| GB9814640D0 (en) | 1998-07-06 | 1998-09-02 | Fujisawa Pharmaceutical Co | New use |
| US6015809A (en) | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
| PT1109937E (pt) | 1998-09-02 | 2009-02-10 | Diadexus Inc | Um novo método de diagnóstico, monitorização, identificação de estágio, imagiologia e tratamento de vários cancros |
| US6962980B2 (en) | 1999-09-24 | 2005-11-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| US6468546B1 (en) | 1998-12-17 | 2002-10-22 | Corixa Corporation | Compositions and methods for therapy and diagnosis of ovarian cancer |
| US20030187196A1 (en) | 1998-12-30 | 2003-10-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO2001000814A2 (en) | 1999-06-25 | 2001-01-04 | Universität Zürich | Hetero-associating coiled-coil peptides and screenign method therefor |
| WO2001001137A1 (en) | 1999-06-30 | 2001-01-04 | Children's Medical Center Corporation | Fusion protein and uses thereof |
| DE19937656A1 (de) | 1999-08-13 | 2001-02-15 | Aventis Behring Gmbh | Verwendung von Antithrombin III zur Prophylaxe und Therapie von Erkrankungen |
| EP1294885A2 (en) | 2000-06-30 | 2003-03-26 | Amgen, Inc. | B7-like molecules and uses thereof |
| WO2002002587A1 (en) | 2000-06-30 | 2002-01-10 | Human Genome Sciences, Inc. | B7-like polynucleotides, polypeptides, and antibodies |
| US6537968B1 (en) | 2000-07-24 | 2003-03-25 | Alphamed Pharmaceuticals Corp | Treatment of lupus erythematosus |
| US6891030B2 (en) | 2000-07-27 | 2005-05-10 | Mayo Foundation For Medical Education And Research | T-cell immunoregulatory molecule |
| WO2002064834A1 (en) | 2001-01-04 | 2002-08-22 | Myriad Genetics, Inc. | Novel two-hybrid system and use thereof |
| AU2002224668B2 (en) | 2001-01-26 | 2007-09-20 | Commonwealth Scientific And Industrial Research Organisation | Methods and means for producing efficient silencing construct using recombinational cloning |
| US7132511B2 (en) | 2001-02-19 | 2006-11-07 | Merck Patent Gmbh | Modified anti-EGFR antibodies with reduced immunogenicity |
| AU2003245615A1 (en) | 2002-06-20 | 2004-01-06 | The Regents Of The University Of California | Compositions and methods for modulating lymphocyte activity |
| AU2003258714A1 (en) | 2002-09-06 | 2004-03-29 | Cytos Biotechnology Ag | Immune modulatory compounds and methods |
| US7449300B2 (en) | 2002-11-21 | 2008-11-11 | Mayo Foundation For Medical Education And Research | Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells |
| WO2004084933A1 (en) | 2003-03-28 | 2004-10-07 | Faron Pharmaceuticals Oy | Elevation of adenosine level by cytokine-induced expression of cd73 |
| US20050163772A1 (en) | 2003-06-16 | 2005-07-28 | University Of Washington | B7S1: an immune modulator |
| JP5130044B2 (ja) | 2004-08-03 | 2013-01-30 | イナート・ファルマ | ４ｉｇ−ｂ７−ｈ３およびその対応するｎｋ細胞受容体を標的化する治療および診断方法ならびに組成物 |
| US20080241174A1 (en) * | 2005-03-18 | 2008-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Production And Therapeutic Uses Of Th1-Like Regulatory T Cells |
| ES2772674T3 (es) | 2005-05-12 | 2020-07-08 | Zymogenetics Inc | Composiciones y métodos para modular respuestas inmunitarias |
| KR101600225B1 (ko) | 2005-06-08 | 2016-03-04 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
| CN107723274B (zh) | 2005-09-23 | 2021-05-07 | 塞勒里克斯有限公司 | 具有免疫调节活性的细胞群及其分离方法和用途 |
| MX2008007292A (es) | 2005-12-08 | 2008-10-17 | Univ Louisville Res Found | Composiciones inmunoestimuladoras y metodos. |
| US8241621B2 (en) * | 2006-12-18 | 2012-08-14 | Medistem Laboratories | Stem cell mediated treg activation/expansion for therapeutic immune modulation |
| US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
| US20090142342A1 (en) * | 2006-12-27 | 2009-06-04 | Johns Hopkins University | B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
| AU2007339762B2 (en) * | 2006-12-27 | 2011-03-31 | The Johns Hopkins University | Compositions and methods for treating inflammation and auto-immune diseases |
| EP2111231A4 (en) | 2007-02-13 | 2010-12-15 | Univ Northeastern | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES |
| WO2008100934A1 (en) | 2007-02-14 | 2008-08-21 | Mayo Foundation For Medical Education And Research | B7-h3 in cancer |
| WO2008138017A2 (en) * | 2007-05-08 | 2008-11-13 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for modifying t cell immune responses and inflammation |
| PL2178386T3 (pl) | 2007-07-02 | 2011-04-29 | Sime Darby Malaysia Berhad | Kompozycja tłuszczu do smażenia |
| JP2011503104A (ja) * | 2007-11-09 | 2011-01-27 | カリフォルニア インスティテュート オブ テクノロジー | 免疫調節化合物ならびに関連組成物および方法 |
| CA3069576A1 (en) * | 2008-01-09 | 2009-07-16 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of ocular inflammatory disorders |
| IN2012DN02753A (ja) | 2009-08-31 | 2015-09-18 | Amplimmune Inc | |
| JP2012118516A (ja) | 2010-11-11 | 2012-06-21 | Konica Minolta Business Technologies Inc | ホログラム画像形成方法、静電荷像現像用トナーおよびホログラム画像形成装置 |
| AU2014265142A1 (en) * | 2013-05-17 | 2015-12-24 | Medimmune, Llc | Receptors for B7-H4 |
-
2010
- 2010-08-31 IN IN2753DEN2012 patent/IN2012DN02753A/en unknown
- 2010-08-31 EP EP10752959A patent/EP2473523A2/en not_active Withdrawn
- 2010-08-31 IN IN2764DEN2012 patent/IN2012DN02764A/en unknown
- 2010-08-31 AU AU2010286361A patent/AU2010286361A1/en not_active Abandoned
- 2010-08-31 US US13/392,811 patent/US9011853B2/en active Active
- 2010-08-31 EP EP10748218A patent/EP2473521A2/en not_active Withdrawn
- 2010-08-31 CA CA2772199A patent/CA2772199A1/en not_active Abandoned
- 2010-08-31 JP JP2012527108A patent/JP2013503205A/ja active Pending
- 2010-08-31 CN CN2010800488477A patent/CN102666581A/zh active Pending
- 2010-08-31 CN CN2010800488674A patent/CN102741279A/zh active Pending
- 2010-08-31 JP JP2012527101A patent/JP2013503204A/ja active Pending
- 2010-08-31 AU AU2010286351A patent/AU2010286351A1/en not_active Abandoned
- 2010-08-31 US US13/392,399 patent/US9005616B2/en not_active Expired - Fee Related
- 2010-08-31 WO PCT/US2010/047366 patent/WO2011026122A2/en active Application Filing
- 2010-08-31 CA CA2772204A patent/CA2772204A1/en not_active Abandoned
- 2010-08-31 WO PCT/US2010/047384 patent/WO2011026132A2/en active Application Filing
-
2015
- 2015-04-06 US US14/679,505 patent/US20160039906A1/en not_active Abandoned
- 2015-04-06 US US14/679,497 patent/US9957312B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013503205A5 (ja) | ||
| FR22C1052I1 (fr) | Anticorps anti-cd19 humanises et leur utilisation dans le traitement des tumeurs, de la transplantation et des maladies auto-immunes | |
| JP2020511672A5 (ja) | ||
| BRPI0510881A (pt) | anticorpos contra interleucina-13 humana e usos dos mesmos | |
| EP2352523A4 (en) | IMPROVED ANTI-CD19 ANTIBODIES | |
| TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
| MX2012001882A (es) | Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso. | |
| NO20074554L (no) | Antigen bindende molekyler rettet mot MCSP og som har oker FC reseptor bindende affinitet og effektor funksjon | |
| NZ599875A (en) | Human il-23 antigen binding proteins | |
| MX2011012039A (es) | Anticuerpos bloqueadores anti-dkk-1 y sus usos. | |
| JP2015131795A5 (ja) | ||
| EA201000424A1 (ru) | Антитела к il-23 | |
| WO2008109155A3 (en) | Compositions and methods for treatment of cervical cancer | |
| WO2010021874A3 (en) | Engineered anti-il-13 antibodies, compositions, methods and uses | |
| NO20063926L (no) | N-terminale monopegylerte humane veksthormonkonjugater, fremgangsmater for fremstilling og anvendelse av disse | |
| UA116614C2 (uk) | Антитіло до фактора d і його застосування | |
| EA201000644A1 (ru) | Антитела для лечения и профилактики болезни альцгеймера и их применение | |
| EA200870274A1 (ru) | ПЕПТИДЫ, БЛОКИРУЮЩИЕ СВЯЗЫВАНИЕ IgG C FcRn | |
| WO2010055366A3 (en) | Anti-human il-21 monoclonal antibodies | |
| EP4269563A3 (en) | Anti-gd2 antibodies | |
| WO2006089133A8 (en) | Anti-cd19 antibodies and uses in oncology | |
| WO2009048538A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| MX2007006355A (es) | Epitopes antigenos de interleucina-21, anticuerpos relacionados y su uso en el campo medico. | |
| MX2011012622A (es) | Proteina de enlace de il-13. | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds |